Associate Professor Ts Dr. Baskaran Gunasekaran is a biochemist, researcher, and academic leader with over 15 years of experience in biomedical and translational research. He currently serves as Deputy Director of the Centre of Excellence for Research, Value Innovation and Entrepreneurship (CERVIE) and leads initiatives in research, industry engagement, and postgraduate development at UCSI University. He holds a PhD, MSc, and BSc (Hons) in biochemistry from Universiti Putra Malaysia.
Dr. Baskaran’s research focuses on metabolic and clinical biochemistry, nutraceuticals, natural products, cancer biology, and precision medicine. His work explores the molecular mechanisms underlying hypercholesterolemia, obesity, diabetes, and cancer, with particular emphasis on phytotherapeutics, enzyme inhibition, transcriptomics, and toxicity evaluation of bioactive compounds. He has extensive expertise in studying cholesterol metabolism pathways, including HMG-CoA reductase inhibition, pancreatic lipase inhibition, and the therapeutic potential of plant-derived compounds and phytosterols.
In recent years, his research has expanded into transcriptomics and long non-coding RNA (lncRNA) biology, particularly in colorectal cancer and other chronic diseases. He actively employs advanced molecular approaches, including NanoString nCounter technology, to elucidate disease mechanisms and identify novel therapeutic targets.
Associate Professor Ts Dr. Baskaran Gunasekaran is a biochemist, researcher, and academic leader with over 15 years of experience in biomedical and translational research. He currently serves as Deputy Director of the Centre of Excellence for Research, Value Innovation and Entrepreneurship (CERVIE) and leads initiatives in research, industry engagement, and postgraduate development at UCSI University. He holds a PhD, MSc, and BSc (Hons) in biochemistry from Universiti Putra Malaysia.
Dr. Baskaran’s research focuses on metabolic and clinical biochemistry, nutraceuticals, natural products, cancer biology, and precision medicine. His work explores the molecular mechanisms underlying hypercholesterolemia, obesity, diabetes, and cancer, with particular emphasis on phytotherapeutics, enzyme inhibition, transcriptomics, and toxicity evaluation of bioactive compounds. He has extensive expertise in studying cholesterol metabolism pathways, including HMG-CoA reductase inhibition, pancreatic lipase inhibition, and the therapeutic potential of plant-derived compounds and phytosterols.
In recent years, his research has expanded into transcriptomics and long non-coding RNA (lncRNA) biology, particularly in colorectal cancer and other chronic diseases. He actively employs advanced molecular approaches, including NanoString nCounter technology, to elucidate disease mechanisms and identify novel therapeutic targets.